TY - JOUR
T1 - Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice
AU - Salous, Abdel K.
AU - Panchatcharam, Manikandan
AU - Sunkara, Manjula
AU - Mueller, Paul
AU - Dong, Anping
AU - Wang, Yuhuan
AU - Graf, Gregory A.
AU - Smyth, Susan S.
AU - Morris, Andrew J.
PY - 2013/10
Y1 - 2013/10
N2 - Lysophosphatidic acid (LPA) is a bioactive lipid mediator. Concentrations of the major LPA species in mouse plasma decreased uniformly following administration of a potent selective inhibitor of the LPA-generating lysophospholipase D autotaxin, identifying an active mechanism for removal of LPA from the circulation. LPA, akylglycerol phosphate (AGP), sphingosine 1-phosphate (S1P), and a variety of structural mimetics of these lipids, including phosphatase- resistant phosphonate analogs of LPA, were rapidly eliminated (t1/2 < 30 s) from the circulation of mice following intravenous administration of a single bolus dose without significant metabolism in situ in the blood. These lipids accumulated in the liver. Elimination of intravenously administered LPA was blunted by ligation of the hepatic circulation, and ~90% of LPA administered through the portal vein was accumulated by the isolated perfused mouse liver at first pass. At early times following intravenous administration, more LPA was associated with a nonparenchymal liver cell fraction than with hepatocytes. Primary cultures of nonparenchymal liver cells rapidly assimilated exogenously provided LPA. Our results identify hepatic uptake as an important determinant of the bioavailability of LPA and bioactive lysophospholipid mimetics and suggest a mechanism to explain changes in circulating LPA levels that have been associated with liver dysfunction in humans.
AB - Lysophosphatidic acid (LPA) is a bioactive lipid mediator. Concentrations of the major LPA species in mouse plasma decreased uniformly following administration of a potent selective inhibitor of the LPA-generating lysophospholipase D autotaxin, identifying an active mechanism for removal of LPA from the circulation. LPA, akylglycerol phosphate (AGP), sphingosine 1-phosphate (S1P), and a variety of structural mimetics of these lipids, including phosphatase- resistant phosphonate analogs of LPA, were rapidly eliminated (t1/2 < 30 s) from the circulation of mice following intravenous administration of a single bolus dose without significant metabolism in situ in the blood. These lipids accumulated in the liver. Elimination of intravenously administered LPA was blunted by ligation of the hepatic circulation, and ~90% of LPA administered through the portal vein was accumulated by the isolated perfused mouse liver at first pass. At early times following intravenous administration, more LPA was associated with a nonparenchymal liver cell fraction than with hepatocytes. Primary cultures of nonparenchymal liver cells rapidly assimilated exogenously provided LPA. Our results identify hepatic uptake as an important determinant of the bioavailability of LPA and bioactive lysophospholipid mimetics and suggest a mechanism to explain changes in circulating LPA levels that have been associated with liver dysfunction in humans.
KW - Autotaxin
KW - Lipid phosphate phosphatase
KW - Mass spectrometry
KW - Transcellular uptake
UR - http://www.scopus.com/inward/record.url?scp=84884147849&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884147849&partnerID=8YFLogxK
U2 - 10.1194/jlr.M039685
DO - 10.1194/jlr.M039685
M3 - Article
C2 - 23948545
AN - SCOPUS:84884147849
SN - 0022-2275
VL - 54
SP - 2775
EP - 2784
JO - Journal of Lipid Research
JF - Journal of Lipid Research
IS - 10
ER -